{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:07:19Z","timestamp":1761163639121,"version":"build-2065373602"},"reference-count":16,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:00:00Z","timestamp":1434672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,7]]},"abstract":"\n Study Objective<\/jats:title>\n \n To review five cases of severe adverse reactions after vaccination with the 23\u2010valent pneumococcal polysaccharide vaccine (\n PPSV<\/jats:styled-content>\n 23) in pediatric and adolescent patients with sickle cell disease (\n SCD<\/jats:styled-content>\n ), and to evaluate the prevalence of adverse reactions to\n PPSV<\/jats:styled-content>\n 23 in patients with\n SCD<\/jats:styled-content>\n by analyzing data from the Vaccine Adverse Event Reporting System (\n VAERS<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n \n Case series and retrospective analysis of data from the\n VAERS<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n \n Medical records from a tertiary care hospital and the\n VAERS<\/jats:styled-content>\n database.\n <\/jats:p>\n <\/jats:sec>\n \n Measurements and Main Results<\/jats:title>\n \n Five cases of severe adverse reactions after vaccination with\n PPSV<\/jats:styled-content>\n 23 in pediatric and adolescent patients with\n SCD<\/jats:styled-content>\n (aged 2\u201322\u00a0years) were reviewed. The adverse reactions occurred within 24\u00a0hours after immunization, and all five patients required medical attention. Analysis of data from the\n VAERS<\/jats:styled-content>\n found that\n PPSV<\/jats:styled-content>\n 23 was the most commonly reported vaccine causing adverse events in patients with\n SCD<\/jats:styled-content>\n , accounting for 62% of all vaccine\u2010induced adverse events. This rate is significantly higher than the rate of adverse events related to\n PPSV<\/jats:styled-content>\n 23 in patients with human immunodeficiency virus (\n HIV<\/jats:styled-content>\n ) or asthma (62% vs 16%, p<0.0001). The reported number of adverse reactions in pediatric patients (<\u00a018\u00a0years old) with\n SCD<\/jats:styled-content>\n was 4 times higher than that reported in adult patients (18\u201339\u00a0years old) with\n SCD<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n The risk of developing severe adverse reactions to\n PPSV<\/jats:styled-content>\n 23 is greater in patients with\n SCD<\/jats:styled-content>\n than in patients with\n HIV<\/jats:styled-content>\n or asthma, and especially in pediatric and adolescent patients with\n SCD<\/jats:styled-content>\n compared with their adult counterparts. Health care professionals should closely monitor for potential adverse events after\n PPSV<\/jats:styled-content>\n 23 vaccination or revaccination in patients with\n SCD<\/jats:styled-content>\n , adhere to the recommended time interval between\n PCV<\/jats:styled-content>\n 13 and\n PPSV<\/jats:styled-content>\n 23 administration, and possibly consider avoiding simultaneous administration of other vaccines with\n PPSV<\/jats:styled-content>\n 23.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/phar.1607","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T05:07:27Z","timestamp":1434690447000},"page":"696-700","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease"],"prefix":"10.1002","volume":"35","author":[{"given":"Jin","family":"Han","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Opeyemi","family":"Kemiki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Section\u00a0of Hematology\u2010Oncology University of Illinois at Chicago Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis L.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Section\u00a0of Hematology\u2010Oncology University of Illinois at Chicago Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela E.","family":"Rivers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Section\u00a0of Hematology\u2010Oncology University of Illinois at Chicago Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,19]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children \u2013 use of 13\u2010valent pneumococcal conjugate vaccine and 23\u2010valent pneumococcal polysaccharide vaccine \u2010 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Nuorti JP","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70055-4"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/136.Supplement.S25"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.09.052"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/516781"},{"key":"e_1_2_5_7_1","first-page":"816","article-title":"Use of 13\u2010valent pneumococcal conjugate vaccine and 23\u2010valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_5_8_1","unstructured":"Pneumovax 23.[package insert]. Whitehouse Station NJ: Merck & Co. Inc.;2011."},{"key":"e_1_2_5_9_1","first-page":"19","article-title":"Pneumococcal polysaccharide immunization of children with sickle cell disease. I. Clinical reactions to immunization and relationship to preimmunization antibody","volume":"4","author":"Overturf GD","year":"1982","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198305000-00005"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420230051007"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61029-X"},{"key":"e_1_2_5_13_1","first-page":"1","article-title":"Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_5_14_1","first-page":"1","article-title":"Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_5_15_1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/B978-1-4160-3611-1.50028-3","volume-title":"Vaccines","author":"Jackson LA","year":"2008"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9888-3"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1886"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1607","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:32:45Z","timestamp":1761067965000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,19]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/phar.1607"],"URL":"https:\/\/doi.org\/10.1002\/phar.1607","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2015,6,19]]},"assertion":[{"value":"2015-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}